MLTX
MoonLake Immunotherapeutics
NASDAQ: MLTX · HEALTHCARE · BIOTECHNOLOGY
$17.23
+3.86% today
Updated 2026-08-12
Market cap
$1.47B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.88
Dividend yield
—
52W range
$6 – $63
Volume
1.3M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.5
Quality
C+3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-0.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →218 stocks currently score above 75
Price targets
Analyst target
$28.00
+62.51%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy10 Buy2 Hold2 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.40x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -0.67 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-66.29M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-64.51M | $-36.01M | $-118.94M | $-227.32M | $-69.71M |
| EPS | — | — | — | — | $-3.88 |
| Free cash flow | $-55.91M | $-43.06M | $-117.11M | $-196.04M | $-66.29M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
MoonLake Immunotherapeutics trades at $17.23. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -0.67, it sits in the distress.
Frequently asked questions
What is MoonLake Immunotherapeutics's stock price?
MoonLake Immunotherapeutics (MLTX) trades at $17.23.
Is MoonLake Immunotherapeutics overvalued?
MoonLake Immunotherapeutics carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of MoonLake Immunotherapeutics (MLTX)?
The 12-month analyst consensus target is $28.00, about 62.5% above the current $17.23. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
MoonLake Immunotherapeutics's Altman Z-Score is -0.67, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-77.80%
Beta1.07
50D MA$19.05
200D MA$16.38
Shares out0.09B
Float0.04B
Short ratio—
Avg volume1.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—